This is especially pronounced for BTK inhibitors because of the potential immunosuppressive effect reported with ibrutinib.15,19 This may be of potential danger in mounting a response to COVID-19 but may be of benefit in reducing late and severe immune-mediated complications. The gene discussed is BTK; the disease is COVID-19.